The EP4 prostanoid receptor is one of four receptor subtypes for prostaglandin E 2. It
belongs to the family of G protein–coupled receptors. It was originally identified, similar to …

Simple Summary Inflammation is like the proverbial double-edged sword. Controlled short-
term inflammation could be a protective response while uncontrolled inflammation sustains …

Pulmonary hypertension (PH) is characterized by increased proliferation and apoptosis
resistance of pulmonary artery smooth muscle cells (PASMCs). Forkhead box O (FoxO) …

Phenotypic alterations in resident vascular cells contribute to the vascular remodeling
process in diseases such as pulmonary (arterial) hypertension [P (A) H]. How the molecular …

Pulmonary arterial hypertension is a chronic, progressive disease characterized by
elevation of pulmonary artery pressure and pulmonary vascular resistance that ultimately …

The prostacyclin analogues, iloprost and treprostinil are extensively used in treating
pulmonary hypertension. Their binding profile and corresponding biochemical cellular …

Identification of the primary products of cyclo‐oxygenase (COX)/prostaglandin synthase (s),
which occurred between 1958 and 1976, was followed by a classification system for …

Rationale: Prostacyclin analogs, used to treat idiopathic pulmonary arterial hypertension
(IPAH), are assumed to work through prostacyclin (IP) receptors linked to cyclic AMP (cAMP) …

Pulmonary arterial hypertension (PAH) is a progressive disease of distal pulmonary arteries
in which patients suffer from elevated pulmonary arterial pressure, extensive vascular …

Objective—Pulmonary arterial hypertension is a progressive pulmonary vascular disorder
with high morbidity and mortality. Compelling evidence suggests that receptor tyrosine …